Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis

Full text
Author(s):
Mendes da Silva de Bastiani, Fernanda Walt [1] ; Spadari, Cristina de Castro [1] ; Rocha de Matos, Jenyffer Kelly [2] ; Salata, Giovanna Cassone [2] ; Lopes, Luciana Biagini [2] ; Ishida, Kelly [1]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Lab Antifungal Chemotherapy, Sao Paulo - Brazil
[2] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Lab Nanomed & Drug Delivery Syst, Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: FRONTIERS IN MICROBIOLOGY; v. 10, JAN 10 2020.
Web of Science Citations: 0
Abstract

Topical drug administration is frequently used for the treatment of vaginal candidiasis; however, most formulations using this route do not provide prolonged drug release. Our aim was to evaluate the antifungal efficacy of amphotericin B (AMB) and miltefosine (MFS) incorporated in nanocarriers for sustained drug release, in a murine model of vaginal candidiasis. AMB and MFS were incorporated in different topical formulations, namely: conventional vaginal cream (daily dose for 6 days; MFS-CR and AMB-CR groups), microemulsion that transforms into a liquid crystalline gel in situ (single dose, or in three doses, every 48 h; AMB-ME and MFS-ME groups) and alginate nanoparticles (single dose; MFS-AN group). Formulations were administered intravaginally in BALB/c female mice 24 h post-infection by Candida albicans yeasts. On the 7th day post-infection the animals were euthanized for mycological and histological analyses. Formulation persistence in the vaginal canal was assessed for 7 days by in vivo imaging, using nanocarriers labeled with Alexa-Fluor 647. AMB-ME(3x), MFS-ME(3x), and MFS-AN(1x) formulations were able to control fungal infection at comparable levels to those vaginal cream formulations. Notably, a single dose of MFS-AN was sufficient to reduce the fungal burden as effectively as MFS-ME(3x) and MFS-CR(6x). In vivo imaging showed that nanocarriers allowed prolonged antifungal activity by intravaginal administration reducing drug administration frequency. Therefore, AMB and MFS incorporated into a microemulsion and MFS encapsulated in alginate nanoparticles could be effective therapeutic alternatives for vaginal candidiasis, likely due to the sustained antifungal activity provided by these nanocarriers. (AU)

FAPESP's process: 17/19374-9 - Echinocandins in the control of infections associated to polymicrobial biofilms of Candida spp. and bacteria such as Stapholococcus aureus and Pseudomonas aeruginosa
Grantee:Kelly Ishida
Support Opportunities: Regular Research Grants
FAPESP's process: 15/07993-0 - ENCAPSULATION OF MILTEFOSINE INTO MICROPARTICLES OF ALGINATE AND EVALUATION OF EFFECTS "IN VITRO" AND "IN VIVO" ON MURINE MODEL OF PULMONARY CRYPTOCOCCOSIS
Grantee:Kelly Ishida
Support Opportunities: Regular Research Grants
FAPESP's process: 18/13877-1 - Nanocarriers for localized treatment and chemoprevention of breast tumors
Grantee:Luciana Biagini Lopes
Support Opportunities: Research Grants - Young Investigators Grants - Phase 2